MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Search

Charles River Laboratories International Inc

Fechado

SetorSaúde

199.61 -1.07

Visão Geral

Variação de preço das ações

24h

Atual

Mín

199.11

Máximo

200.55

Indicadores-chave

By Trading Economics

Rendimento

2.9M

56M

Vendas

-27M

1B

EPS

2.43

Margem de lucro

5.529

Funcionários

18,700

EBITDA

-23M

198M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

-0.71% downside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.2B

10B

Abertura anterior

200.68

Fecho anterior

199.61

Sentimento de Notícias

By Acuity

50%

50%

157 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

31 de dez. de 2025, 22:20 UTC

Grandes Movimentos do Mercado

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 de dez. de 2025, 17:31 UTC

Grandes Movimentos do Mercado

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 de dez. de 2025, 16:30 UTC

Grandes Movimentos do Mercado

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 de dez. de 2025, 15:19 UTC

Grandes Movimentos do Mercado

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 de dez. de 2025, 15:17 UTC

Grandes Movimentos do Mercado

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 de dez. de 2025, 14:37 UTC

Grandes Movimentos do Mercado

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31 de dez. de 2025, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

31 de dez. de 2025, 21:13 UTC

Aquisições, Fusões, Aquisições de Empresas

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 de dez. de 2025, 20:40 UTC

Conversa de Mercado

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 de dez. de 2025, 20:22 UTC

Conversa de Mercado

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 de dez. de 2025, 19:50 UTC

Conversa de Mercado

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 de dez. de 2025, 19:31 UTC

Conversa de Mercado

Precious Metals Cap Off Record Runs -- Market Talk

31 de dez. de 2025, 18:50 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

31 de dez. de 2025, 18:50 UTC

Conversa de Mercado

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 de dez. de 2025, 17:17 UTC

Conversa de Mercado

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 de dez. de 2025, 17:16 UTC

Grandes Movimentos do Mercado

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 de dez. de 2025, 17:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

31 de dez. de 2025, 17:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 de dez. de 2025, 15:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 de dez. de 2025, 15:54 UTC

Conversa de Mercado

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 de dez. de 2025, 15:02 UTC

Grandes Movimentos do Mercado

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 de dez. de 2025, 14:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 de dez. de 2025, 14:20 UTC

Conversa de Mercado

Crude Futures On Track to End the Year With Losses -- Market Talk

31 de dez. de 2025, 13:46 UTC

Conversa de Mercado

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31 de dez. de 2025, 13:01 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31 de dez. de 2025, 11:10 UTC

Conversa de Mercado

Copper Remains in Touching Distance of Record Highs -- Market Talk

31 de dez. de 2025, 10:46 UTC

Conversa de Mercado

Euro on Track For Strong Annual Performance -- Market Talk

31 de dez. de 2025, 10:25 UTC

Conversa de Mercado

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31 de dez. de 2025, 10:23 UTC

Conversa de Mercado

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31 de dez. de 2025, 09:33 UTC

Conversa de Mercado

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

-0.71% parte inferior

Previsão para 12 meses

Média 200.55 USD  -0.71%

Máximo 225 USD

Mínimo 170 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

7

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

157 / 374 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat